e-learning
resources
Stockholm 2002
Sunday 15.09.2002
Asthma and COPD: pharmacology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients
C. Sevinc, E. Ceylan, S. Sahbaz, F. Fidan, A. Hayretdag, O. Kilinc, O. Itil, A. H. Cimrin, E. S. Ucan, M. Gok, A. Akkoclu (Izmir, Turkey)
Source:
Annual Congress 2002 - Asthma and COPD: pharmacology
Session:
Asthma and COPD: pharmacology
Session type:
Thematic Poster Session
Number:
753
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Sevinc, E. Ceylan, S. Sahbaz, F. Fidan, A. Hayretdag, O. Kilinc, O. Itil, A. H. Cimrin, E. S. Ucan, M. Gok, A. Akkoclu (Izmir, Turkey). Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients. Eur Respir J 2002; 20: Suppl. 38, 753
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
Effect of inhaled beta2 agonist on lung compliance in patients with COPD with poor bronchodilator response
Source: Eur Respir J 2006; 28: Suppl. 50, 428s
Year: 2006
Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006
Long-acting β
2
-agonists provide greater benefit compared to leukotriene antagonists when added to inhaled corticosteroids in patients with symptomatic asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004
The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA)
Source: Eur Respir J 2005; 26: Suppl. 49, 717s
Year: 2005
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
The impact of preventive treatment with long-acting β
2
adrenergics agonists and inhaled glucocorticoids in the morbility and mortality of 1.543 events of severe acute exacerbations of asthma
Source: Annual Congress 2009 - Epidemiology of atopy and asthma
Year: 2009
Are inhaled corticosteroids increasing the “load” for some patients with COPD?
Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept